文献速递前列腺癌

中危前列腺癌的主动监测

Active surveillance for intermediate-risk prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2016-11-01

该综述检索PubMed相关原创研究,分析中危前列腺癌患者主动监测的结局。中危定义各研究不一,Gleason 7患者临床进展率更高且更可能接受治疗,Gleason 6中危患者结局与低危相似,Gleason 7患者转移风险似乎更高。

要点

  • 中危前列腺癌主动监测的纳入标准尚未统一,各研究定义存在差异。
  • Gleason 7患者临床进展率更高,更可能接受前列腺定向治疗,转移风险似乎更高。
  • Gleason 6中危患者主动监测结局与低危患者相似。

核心结论

  • 中危前列腺癌患者接受主动监测后最终接受前列腺定向治疗的风险更高,但部分患者并未显著损害长期治愈机会。
  • Gleason模式4超过微量的患者须仔细选择和监测早期进展迹象,且可能转移风险增加。
  • 结合先进影像和生物标志物技术可能使未来治疗决策个体化并改善总体监测策略。

研究设计与样本

  • 综述:检索PubMed所有描述前列腺癌主动监测结局的相关原创出版物。
  • 研究中危特征患者(按原研究者定义)的结局,并与接受立即治疗的相似风险男性比较。

主要发现

  • 初始主动监测的前列腺癌患者癌症特异性生存与立即根治性干预发表结果相似。
  • 共5个已发表的主动监测系列描述了部分中危特征男性的结局。
  • 各研究间中危定义存在差异。
  • Gleason 7疾病男性临床进展率更高,且随时间更可能接受治疗。
  • Gleason 6疾病中危男性结局与低危男性相似。

关键数值与推荐

  • 共5个已发表的主动监测系列描述了部分中危特征男性的结局。
  • 各研究间中危定义存在差异。
  • Gleason 7疾病男性临床进展率更高,且更可能随时间接受治疗。
  • Gleason 6疾病中危男性结局与低危男性相似。
  • Gleason 7疾病男性似乎转移风险更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with intermediate-risk featuresMethods:PubMed was queried for all relevant original publications describing outcomes for men with prostate cancer managed with AS. Outcomes for patients with intermediate-risk features as defined by the primary investigators were studied when available and compared with similar risk men undergoing immediate treatment. RESULTS: Cancer-specific survival for men managed initially with AS is similar to results published with immediate radical intervention. A total of five published AS series describe some outcomes for men with intermediate-risk features. Definitions of intermediate risk vary between studies. Men with Gleason 7 disease experience higher rates of clinical progression and are more likely to undergo treatment over time. Intermediate-risk men with Gleason 6 disease have similar outcomes to low-risk men. Men with Gleason 7 disease appear at higher risk for metastatic disease. Novel technologies including imaging and biomarkers may assist with patient selection and disease surveillance. CONCLUSIONS: The contemporary experiences of AS for men with intermediate-risk features suggest that although these men are at higher risk for eventual prostate-directed treatment, some are not significantly compromising chances for longer-term cure. Men with more than minimal Gleason pattern 4, however, must be carefully selected and surveyed for early signs of progression and may be at increased risk of metastases. Incorporating information from advanced imaging and biomarker technology will likely individualize future treatment decisions while improving overall surveillance strategies.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Dall'Era MA, Klotz L. Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis. 2016. PMID: 27801900. doi:10.1038/pcan.2016.51

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。